123 related articles for article (PubMed ID: 10430048)
1. Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones.
Pette M; Muraro PA; Pette DF; Dinter H; McFarland HF; Martin R
J Neuroimmunol; 1999 Aug; 98(2):147-56. PubMed ID: 10430048
[TBL] [Abstract][Full Text] [Related]
2. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation.
Jimenez JL; Punzón C; Navarro J; Muñoz-Fernández MA; Fresno M
J Pharmacol Exp Ther; 2001 Nov; 299(2):753-9. PubMed ID: 11602691
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK
J Pharmacol Exp Ther; 1997 Jul; 282(1):505-12. PubMed ID: 9223593
[TBL] [Abstract][Full Text] [Related]
6. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2.
Giembycz MA; Corrigan CJ; Seybold J; Newton R; Barnes PJ
Br J Pharmacol; 1996 Aug; 118(8):1945-58. PubMed ID: 8864528
[TBL] [Abstract][Full Text] [Related]
7. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
Liang L; Beshay E; Prud'homme GJ
Diabetes; 1998 Apr; 47(4):570-5. PubMed ID: 9568689
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
9. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.
Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R
Arthritis Res Ther; 2003; 5(6):R317-28. PubMed ID: 14680506
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases.
Bielekova B; Lincoln A; McFarland H; Martin R
J Immunol; 2000 Jan; 164(2):1117-24. PubMed ID: 10623864
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Sommer N; Martin R; McFarland HF; Quigley L; Cannella B; Raine CS; Scott DE; Löschmann PA; Racke MK
J Neuroimmunol; 1997 Oct; 79(1):54-61. PubMed ID: 9357447
[TBL] [Abstract][Full Text] [Related]
12. Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones.
Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK
Biochem Pharmacol; 1997 Apr; 53(7):1055-60. PubMed ID: 9174120
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein.
Ekholm D; Hemmer B; Gao G; Vergelli M; Martin R; Manganiello V
J Immunol; 1997 Aug; 159(3):1520-9. PubMed ID: 9233651
[TBL] [Abstract][Full Text] [Related]
14. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
Blease K; Burke-Gaffney A; Hellewell PG
Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
[TBL] [Abstract][Full Text] [Related]
15. Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells.
Yoshimura T; Kurita C; Nagao T; Usami E; Nakao T; Watanabe S; Kobayashi J; Yamazaki F; Tanaka H; Nagai H
Gen Pharmacol; 1997 Oct; 29(4):633-8. PubMed ID: 9352314
[TBL] [Abstract][Full Text] [Related]
16. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
[TBL] [Abstract][Full Text] [Related]
17. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
18. Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99).
Hemmer B; Vergelli M; Calabresi P; Huang T; McFarland HF; Martin R
J Neurosci Res; 1996 Sep; 45(6):852-62. PubMed ID: 8892097
[TBL] [Abstract][Full Text] [Related]
19. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.
Chi ZL; Hayasaka S; Zhang XY; Hayasaka Y; Cui HS
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2497-502. PubMed ID: 15277469
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
Jones NA; Leport M; Holand T; Vos T; Morgan M; Fink M; Pruniaux MP; Berthelier C; O'Connor BJ; Bertrand C; Page CP
Pulm Pharmacol Ther; 2007; 20(1):60-8. PubMed ID: 16427796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
